HIFU treatment
DeviceHIFU for the management of cervical HR-HPV-related LSIL
NCT Number: NCT07461064
The majority of low-grade pre-invasive lesions of cervix (low-grade squamous intraepithelial lesions, LSIL).will regress spontaneously over 2 years and immediate treatment may not be necessary. According to the Hong Kong College of Obstetricians and Gynaecologists (HKCOG), if a low-grade lesion is confirmed by colposcopy and biopsy, the patient can be observed and followed up with HPV testing or co-testing at 12 months, irrespective of age. This randomized controlled study is to determine whether high-intensity focused ultrasound (HIFU) treatment of low-grade pre-invasive lesions of cervix, can cause regression of these lesions in more patients within a specific time when compared to observation as a standard management according to HKCOG Guidelines. All eligible patients will be randomized in a 1:1 ratio into 2 groups: high-intensity focused ultrasound (HIFU) or Observation group. Background information of the patients such as age, parity, body mass index, smoking status and the presence of chronic medical disease will be collected. All patients with cervical HR-HPV status will be tested. Patients randomized into HIFU group will receive HIFU treatment within 2 weeks after randomization. Those randomized into Observation group will have no intervention. All patients will attend follow-up at 6 and 12 months after randomization, during which cervical smear for cytology (with cytopathologists blinded to the treatment group) and HR-HPV testing will be performed. The rate of cytological LSIL regression and HR-HPV clearance rates at 6 and 12 months in both groups will be analyzed. Patients will be referred back to colposcopy clinic for repeat colposcopy if needed according to HKCOG Guidelines. At the 12-month follow-up visit, if referral to repeat colposcopy is not needed, patients will be referred back to their primary care physicians, Department of Health Family Health Service, Family Planning Association or other primary care centres for follow-up cervical smears.
Trial opening soon.
Get Notified18 year–55 year
Female
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants be considered withdrawn from study or excluded from analysis
HIFU for the management of cervical HR-HPV-related LSIL
Time frame: 12 months
Time frame: 12 months
The efficacy of HIFU in clearing cervical HR-HPV-related HPV will be compared to observation. Both HIFU and Observation group will have HPV testing at 6 and 12 months after recruitment, and the incidence of HR-HPV in both groups will be analyzed.
Time frame: 12 months
The number of participants that required repeat colposcopy for persistent abnormal cervical smear in HIFU and Observation group will be compared.
Time frame: 6 months
The treatment time, intraoperative blood loss, intraoperative pain level using visual analog scale (VAS) pain score, and other discomfort are recorded. Patients will be called in 1 week for any postoperative side effects or complications such as discharge, bleeding, pain (including the VAS pain score) or discomfort, for which, additional telephone or clinic follow-up will be arranged if necessary. The visual analog scale pain score will range from a minimum value of 0 to a maximum value of 10, with higher scores mean worse pain level.
Time frame: 1 months
The level of patient satisfaction in using HIFU in the treatment of cervical LSIL level will be evaluated using visual analog scale (VAS) score, immediately after, and 1 month after HIFU treatment. The visual analog scale patient satisfaction score will range from a minimum value of 0 to a maximum value of 5, with higher scores mean higher satisfaction.
Contact information is provided by the study sponsor or research team.
Queen Mary Hospital, Hong Kong
Other
High-Intensity Focused Ultrasound (HIFU) Versus Observation for Low-Grade Squamous Intraepithelial Lesions of Cervix: A Randomized Controlled Trial
Acronym: HIFU Colpo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07697196
Communicable Diseases, DNA Virus Infections
Milan, Italy
View Trial DetailsNCT06075264
Communicable Diseases, DNA Virus Infections
Fort Myers, Florida, United States
View Trial DetailsNCT05555862
AIN 2/3, Anal Dysplasia
Chicago, Illinois, United States
View Trial DetailsNCT00788164
Cervical Cancer, Female Urogenital Diseases
Baltimore, Maryland, United States
View Trial Details